Extract The European Respiratory Society and European Sleep Research Society statement on the treatment of central sleep apnoea (CSA) with adaptive servo-ventilation (ASV) provides a thorough and timely update on this important topic [1]. However, the statement conflates all forms of ASV as if these represent a generic intervention with uniform properties and treatment outcomes in patients with heart failure and reduced ejection fraction (HFrEF), when randomised trials indicate otherwise. Furthermore, it asserts, without corroborating data, that the ADVENT-HF trial was "statistically underpowered, particularly, to definitively address safety issues".
Extract The European Respiratory Society and European Sleep Research Society statement on the treatment of central sleep apnoea (CSA) with adaptive servo-ventilation (ASV) provides a thorough and timely update on this important topic [1]. However, the statement conflates all forms of ASV as if these represent a generic intervention with uniform properties and treatment outcomes in patients with heart failure and reduced ejection fraction (HFrEF), when randomised trials indicate otherwise. Furthermore, it asserts, without corroborating data, that the ADVENT-HF trial was "statistically underpowered, particularly, to definitively address safety issues".